1
|
Mohler J, Bahnson RR, Boston B, Busby JE,
D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, et
al: NCCN clinical practice guidelines in oncology: Prostate cancer.
J Natl Compr Canc Netw. 8:162–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Adebamowo CA and Akarolo-Anthony S: Cancer
in Africa: Opportunities for collaborative research and training.
Afr J Med Med Sci (38 Suppl 2). S5–S13. 2009.
|
3
|
Barton MB, Frommer M and Shafiq J: Role of
radiotherapy in cancer control in low-income and middle-income
countries. Lancet Oncol. 7:584–595. 2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kigula Mugambe JB and Wegoye P: Pattern
and experience with cancers treated with the Chinese GWGP80 cobalt
unit at Mulago Hospital, Kampala. East Afr Med J. 77:523–525.
2000.PubMed/NCBI
|
5
|
Page BR, Hudson AD, Brown DW, Shulman AC,
Abdel-Wahab M, Fisher BJ and Patel S: Cobalt, linac, or other: What
is the best solution for radiation therapy in developing countries?
Int J Radiat Oncol Biol Phys. 89:476–480. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zelefsky MJ, Valicenti RK, Hunt M and
Perez CA: Low-risk prostate cancer. Perez and Brady's Principles
and Practice of Radiation Oncology. Halperin EC, Perez CA, Brady
LW, Wazer DE, Freeman C and Prosnitz LR: 5th. Lippincott Williams
& Wilkins; pp. 1280–1311. 2007
|
7
|
Hussey DH: Carcinoma of the prostate.
Textbook of Radiotherapy. Fletcher GH: 3rd. Lea & Febiger;
Philadelphia: pp. 894–914. 1980
|
8
|
Pilepich MV, Prasad SC and Perez CA:
Computed tomography in definitive radiotherapy of prostatic
carcinoma, part 2: Definition of target volume. Int J Radiat Oncol
Biol Phys. 8:235–239. 1982. View Article : Google Scholar : PubMed/NCBI
|
9
|
Boehmer D, Maingon P, Poortmans P, Baron
MH, Miralbell R, Remouchamps V, Scrase C, Bossi A and Bolla M;
EORTC radiation oncology group, : Guidelines for primary
radiotherapy of patients with prostate cancer. Radiother Oncol.
79:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Bentzen SM, Constine LS, Deasy JO,
Eisbruch A, Jackson A, Marks LB, Ten Haken RK and Yorke ED:
Quantitative analyses of normal tissue effects in the clinic
(QUANTEC): An introduction to the scientific issues. Int J Radiat
Oncol Biol Phys. 76 (3 Suppl):S3–S9. 2010. View Article : Google Scholar : PubMed/NCBI
|
11
|
Dearnaley DP, Hall E, Lawrence D, Huddart
RA, Eeles R, Nutting CM, Gadd J, Warrington A, Bidmead M and
Horwich A: Phase III pilot study of dose escalation using conformal
radiotherapy in prostate cancer: PSA control and side effects. Br J
Cancer. 92:488–498. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Khoo VS, Bedford JL, Webb S and Dearnaley
DP: Class solutions for conformal external beam prostate
radiotherapy. Int J Radiat Oncol Biol Phys. 55:1109–1120. 2003.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Smith WL, Lewis C, Bauman G, Rodrigues G,
D'Souza D, Ash R, Ho D, Venkatesan V, Downey D and Fenster A:
Prostate volume contouring: A 3D analysis of segmentation using
3DTRUS, CT, and MR. Int J Radiat Oncol Biol Phys. 67:1238–1247.
2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Villeirs GM, Van Vaerenbergh K, Vakaet L,
Bral S, Claus F, De Neve WJ, Verstraete KL and De Meerleer GO:
Interobserver delineation variation using CT versus combined CT +
MRI in intensity-modulated radiotherapy for prostate cancer.
Strahlenther Onkol. 181:424–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Creak A, Hall E, Horwich A, Eeles R, Khoo
V, Huddart R, Parker C, Griffin C, Bidmead M, Warrington J and
Dearnaley D: Randomised pilot study of dose escalation using
conformal radiotherapy in prostate cancer: Long-term follow-up. Br
J Cancer. 109:651–657. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Bolla M, van Poppel H, Collette L, van
Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset
JF, van Velthoven R, et al: Postoperative radiotherapy after
radical prostatectomy: A randomised controlled trial (EORTC trial
22911). Lancet. 366:572–578. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Swanson GP, Hussey MA, Tangen CM, Chin J,
Messing E, Canby-Hagino E, Forman JD, Thompson IM and Crawford ED;
SWOG 8794, : Predominant treatment failure in postprostatectomy
patients is local: Analysis of patterns of treatment failure in
SWOG 8794. J Clin Oncol. 25:2225–2229. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wiegel T, Bottke D, Steiner U, Siegmann A,
Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, et
al: Phase III postoperative adjuvant radiotherapy after radical
prostatectomy compared with radical prostatectomy alone in pT3
prostate cancer with postoperative undetectable prostate-specific
antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 27:2924–2930. 2009.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Pilepich MV, Winter K, John MJ, Mesic JB,
Sause W, Rubin P, Lawton C, Machtay M and Grignon D: Phase III
radiation therapy oncology group (RTOG) trial 86-10 of androgen
deprivation adjuvant to definitive radiotherapy in locally advanced
carcinoma of the prostate. Int J Radiat Oncol Biol Phys.
50:1243–1252. 2001. View Article : Google Scholar : PubMed/NCBI
|
20
|
Pilepich MV, Winter K, Lawton CA, Krisch
RE, Wolkov HB, Movsas B, Hug EB, Asbell SO and Grignon D: Androgen
suppression adjuvant to definitive radiotherapy in prostate
carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat
Oncol Biol Phys. 61:1285–1290. 2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Bolla M, Van Tienhoven G, Warde P, Dubois
JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C,
Billiet I, et al: External irradiation with or without long-term
androgen suppression for prostate cancer with high metastatic risk:
10-year results of an EORTC randomised study. Lancet Oncol.
11:1066–1073. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Denham JW, Steigler A, Lamb DS, Joseph D,
Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, et
al: Short-term neoadjuvant androgen deprivation and radiotherapy
for locally advanced prostate cancer: 10-year data from the TROG
96.01 randomised trial. Lancet Oncol. 12:451–459. 2011. View Article : Google Scholar : PubMed/NCBI
|
23
|
Nguyen PL, Chen MH, Beard CJ, Suh WW,
Renshaw AA, Loffredo M, McMahon E, Kantoff PW and D'Amico AV:
Radiation with or without 6 months of androgen suppression therapy
in intermediate- and high-risk clinically localized prostate
cancer: A postrandomization analysis by risk group. Int J Radiat
Oncol Biol Phys. 77:1046–1052. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Shipley WU, Verhey LJ, Munzenrider JE,
Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL,
Biggs PJ, et al: Advanced prostate cancer: The results of a
randomized comparative trial of high dose irradiation boosting with
conformal protons compared with conventional dose irradiation using
photons alone. Int J Radiat Oncol Biol Phys. 32:3–12. 1995.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Pollack A, Zagars GK, Starkschall G,
Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA and Rosen
I: Prostate cancer radiation dose response: Results of the M. D.
Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys.
53:1097–1105. 2002. View Article : Google Scholar : PubMed/NCBI
|
26
|
Zietman AL, DeSilvio ML, Slater JD, Rossi
CJ Jr, Miller DW, Adams JA and Shipley WU: Comparison of
conventional-dose vs. high-dose conformal radiation therapy in
clinically localized adenocarcinoma of the prostate: A randomized
controlled trial. JAMA. 294:1233–1239. 2005. View Article : Google Scholar : PubMed/NCBI
|
27
|
Sathya JR, Davis IR, Julian JA, Guo Q,
Daya D, Dayes IS, Lukka HR and Levine M: Randomized trial comparing
iridium implant plus external-beam radiation therapy with
external-beam radiation therapy alone in node-negative locally
advanced cancer of the prostate. J Clin Oncol. 23:1192–1199. 2005.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Peeters ST, Heemsbergen WD, Koper PC, van
Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L and Lebesque
JV: Dose-response in radiotherapy for localized prostate cancer:
Results of the Dutch multicenter randomized phase III trial
comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol.
24:1990–1996. 2006. View Article : Google Scholar : PubMed/NCBI
|
29
|
Viani GA, Stefano EJ and Afonso SL:
Higher-than-conventional radiation doses in localized prostate
cancer treatment: A meta-analysis of randomized, controlled trials.
Int J Radiat Oncol Biol Phys. 74:1405–1418. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Roach M III, Pickett B, Holland J,
Zapotowski KA, Marsh DL and Tatera BS: The role of the urethrogram
during simulation for localized prostate cancer. Int J Radiat Oncol
Biol Phys. 25:299–307. 1993. View Article : Google Scholar : PubMed/NCBI
|
31
|
Liu YM, Ling S, Langen KM, Shinohara K,
Weinberg V, Pouliot J and Roach M III: Prostate movement during
simulation resulting from retrograde urethrogram compared with
‘natural’ prostate movement. Int J Radiat Oncol Biol Phys.
60:470–475. 2004. View Article : Google Scholar : PubMed/NCBI
|
32
|
Lawton CA, Michalski J, El-Naqa I,
Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter
M and Seider M: RTOG GU Radiation oncology specialists reach
consensus on pelvic lymph node volumes for high-risk prostate
cancer. Int J Radiat Oncol Biol Phys. 74:383–387. 2009. View Article : Google Scholar : PubMed/NCBI
|
33
|
Buwenge M, Marinelli A, Deodato F, Macchia
G, Wondemagegnhu T, Salah T, Cammelli S, Uddin AFMK, Sumon MA,
Donati CM, et al: Definition of fields margins for palliative
radiotherapy of pancreatic carcinoma. Mol Clin Oncol. 8:715–718.
2018.PubMed/NCBI
|
34
|
Morganti AG, Marinelli A, Buwenge M,
Macchia G, Deodato F, Massaccesi M, Kigula-Mugambe J, Wondemagegnhu
T, Dawotola D, Caravatta L, et al: Palliative two-dimensional
radiotherapy of pancreatic carcinoma: A feasibility study. Tumori.
99:488–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
35
|
Buwenge M, Cilla S, Cammelli S, Macchia G,
Arcelli A, Farina E, Frakulli R, Panni V, Wondemagegnhu T, Uddin
AFMK, et al: Feasibility of 2D-conformal radiotherapy for
pancreatic carcinoma. Oncol Lett. 16:5939–5945. 2018.PubMed/NCBI
|